Cullinan Therapeutics, Inc. (CGEM)
10.80
-1.69
(-13.53%)
USD |
NASDAQ |
Nov 05, 16:00
11.50
+0.70
(+6.48%)
After-Hours: 07:32
Cullinan Therapeutics SG&A Expense (TTM) : 50.33M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 50.33M |
| March 31, 2026 | 52.28M |
| December 31, 2025 | 54.25M |
| September 30, 2025 | 56.49M |
| June 30, 2025 | 56.21M |
| March 31, 2025 | 55.21M |
| December 31, 2024 | 54.02M |
| September 30, 2024 | 50.10M |
| June 30, 2024 | 47.73M |
| March 31, 2024 | 44.18M |
| December 31, 2023 | 42.49M |
| September 30, 2023 | 43.14M |
| June 30, 2023 | 42.25M |
| March 31, 2023 | 42.73M |
| Date | Value |
|---|---|
| December 31, 2022 | 40.19M |
| September 30, 2022 | 42.37M |
| June 30, 2022 | 37.98M |
| March 31, 2022 | 32.11M |
| December 31, 2021 | 29.14M |
| September 30, 2021 | 28.22M |
| June 30, 2021 | 24.11M |
| March 31, 2021 | 20.91M |
| December 31, 2020 | 15.76M |
| September 30, 2020 | 4.389M |
| June 30, 2020 | 4.48M |
| March 31, 2020 | 2.854M |
| December 31, 2019 | 2.854M |
| September 30, 2019 | 1.677M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Climb Bio, Inc. | 22.86M |
| MapLight Therapeutics, Inc. | 44.09M |
| Arrowhead Pharmaceuticals, Inc. | 172.57M |
| Oncolytics Biotech, Inc. | 16.62M |
| Sangamo Therapeutics, Inc. | 31.64M |